Posted on: December 1, 2019 Posted by: admin Comments: 0

Martin E. Gutierrez, MD, on 2nd line treatment options following 1st line PD-L1 targeting agents

Dr. Gutierrez, Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center, Hackensack Meridian Health, shares how he would treat 2nd line patients who previously received Keytruda or other PD-L1 targeting agents as a part of 1st line therapy


Xem thêm các bài viết về Sức Khỏe:


Leave a Comment